Skip to content

US · EXEL · BIOTECHNOLOGY

Exelixis, Inc. (EXEL) intrinsic value and stock valuation

$64.63as of 2026-11-21 · Mkt cap 14.25B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Exelixis, Inc. DCF and intrinsic value

InvestorsCraft values EXEL with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from EXEL’s statements →

Exelixis, Inc. Graham Number

Graham Number: $22.72d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Alameda, CA 94502 exelixis.com

How the business is doing

Fiscal 2011–2026, USD

Revenue
$2.32B+18.6% 5y CAGRd
20112026
Net income
$782.6M+47.6% 5y CAGRd
20112026
Free cash flow
$844.3M+36.4% 5y CAGRd
20112026
Total equity
$2.16B+2.8% 5y CAGRd
20112026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2026, USD
20262025202320222021
Revenue$2.32B$2.17B$1.83B$1.61B$1.43B
Operating income$872.2M$604.6M$170.9M$201.5M$286.7M
Net income$782.6M$521.3M$207.8M$182.3M$231.1M
EPSd$2.78M$1.76M$646.3K$561.6K$716.8K
Operating cash flow$884.3M$700M$333.3M$362.6M$400.8M
Capital expenditure-$-39.93M-$-66.19M-$-162.97M-$-138.46M-$-64.22M
Free cash flow$844.3M$633.8M$170.4M$224.2M$336.6M
Total assets$2.84B$2.95B$2.94B$3.07B$2.62B
Total debt$173M$190.8M$189.9M$190.2M$51.3M
Net debt-$-309.45M-$-26.55M-$-73.05M-$-311.02M-$-595.9M
Total equity$2.16B$2.24B$2.26B$2.49B$2.21B
Cash and short-term investments$1.06B$1.11B$995.3M$1.31B$1.47B
Income statement
20262025202320222021
Revenue$2.32B$2.17B$1.83B$1.61B$1.43B
Cost of revenue$83.7M$76.2M$72.6M$57.9M$52.9M
Gross profit$2.24B$2.09B$1.76B$1.55B$1.38B
Research and development expenses$825M$910.4M$1.04B$891.8M$693.7M
Selling, general and administrative expenses$518.7M$492.1M$542.7M$459.9M$401.7M
Other expenses$20.5M$85.3M$0.00-$-200K-$-180K
Operating expenses$1.36B$1.49B$1.59B$1.35B$1.1B
Cost and expenses$1.45B$1.56B$1.66B$1.41B$1.15B
Interest income$69.2M$77.2M$86.5M$33.1M$7.67M
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$29.1M$28.8M$25.7M$20.9M$13.6M
Ebitda$921.8M$718.8M$283.2M$255.2M$307.8M
Operating income$872.2M$604.6M$170.9M$201.5M$286.7M
Total other income/expenses, net$69M$77M$86.6M$32.9M$7.49M
Income before tax$941.2M$681.6M$257.5M$234.4M$294.2M
Income tax expense$158.6M$160.4M$49.8M$52.1M$63.1M
Net income$782.6M$521.3M$207.8M$182.3M$231.1M
Weighted average shares outstanding$271.6M$290M$318.2M$321.5M$314.9M
Weighted average diluted shares outstanding$281.9M$296.1M$321.5M$324.6M$322.4M
Balance sheet
20262025202320222021
Cash and short-term investments$1.06B$1.11B$995.3M$1.31B$1.47B
Net receivables$286.9M$265.4M$237.4M$214.8M$285.6M
Inventory$21.7M$22.4M$17.3M$33.3M$27.5M
Total current assets$1.44B$1.47B$1.32B$1.62B$1.83B
Property, plant and equipment, net$441.3M$359.1M$470.9M$345.4M$104M
Goodwill and intangible assets$63.7M$63.7M$63.7M$63.7M$63.7M
Long-term investments$603.6M$637.3M$728.7M$756.7M$371.1M
Total non-current assets$1.4B$1.48B$1.62B$1.45B$781.5M
Total assets$2.84B$2.95B$2.94B$3.07B$2.62B
Accounts payable$29.6M$38.2M$33.8M$32.7M$24.3M
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$7.49M$7.81M
Total current liabilities$405.6M$403.8M$394.3M$324.4M$337.6M
Long-term debt$173M$190.8M$189.9M$190.2M$51.3M
Deferred revenue, non-current$0.00$0.00$0.00$6.58M$8.74M
Total non-current liabilities$277.5M$299.7M$284.2M$258.7M$68M
Capital lease obligations$173M$190.8M$189.9M$190.2M$51.3M
Total liabilities$683.1M$703.5M$678.5M$583.1M$405.6M
Common stock$260K$280K$300K$320K$320K
Retained earnings-$-76.83M-$-98.65M-$-173.35M-$-34.23M-$-216.51M
Accumulated other comprehensive income (loss)$3.48M-$-1.35M-$-3.75M-$-14.52M-$-760K
Total equity$2.16B$2.24B$2.26B$2.49B$2.21B
Total investments$1.18B$1.53B$1.46B$1.56B$1.19B
Total debt$173M$190.8M$189.9M$190.2M$51.3M
Net debt-$-309.45M-$-26.55M-$-73.05M-$-311.02M-$-595.9M
Cash flow statement
20262025202320222021
Net income$782.6M$521.3M$207.8M$182.3M$231.1M
Depreciation and amortization$29.1M$28.8M$25.7M$20.9M$13.6M
Stock-based compensation$113M$93.8M$106.3M$107.6M$119.8M
Change in working capital-$-191.2M-$-13.45M-$-13.97M-$-12.8M-$-39.01M
Accounts receivable-$-21.4M-$-27.95M-$-22.62M$66.9M-$-122.32M
Inventory$12.2M$5.45M-$-12.98M-$-11.68M-$-13.21M
Accounts payable-$-50.15M-$-21.89M$53.3M$23.4M$55.1M
Net cash provided by operating activities$884.3M$700M$333.3M$362.6M$400.8M
Investments in property, plant and equipment-$-8.43M-$-28.43M-$-40.47M-$-27.71M-$-54.23M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$350.4M-$-116.78M-$-26.95M-$-524.41M-$-42.88M
Common stock issued$49.1M$0.00$0.00$0.00$0.00
Common stock repurchased-$-947.51M-$-652.03M-$-550.38M$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-969.59M-$-628.81M-$-546.05M$590K-$-14.8M
Net change in cash$265.1M-$-45.62M-$-239.68M-$-161.21M$343.1M
Cash at end of period$482.5M$217.4M$263M$502.7M$663.9M
Operating cash flow$884.3M$700M$333.3M$362.6M$400.8M
Capital expenditure-$-39.93M-$-66.19M-$-162.97M-$-138.46M-$-64.22M
Free cash flow$844.3M$633.8M$170.4M$224.2M$336.6M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Exelixis, Inc.

        Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.

        CEO
        Michael Morrissey
        Employees
        1.08K
        Beta
        0.42

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Exelixis, Inc. (EXEL)?

        Exelixis, Inc. (EXEL) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is EXEL undervalued?

        EXEL trades at a price of $64.63 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.